Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adamis Pharmaceuticals Corporation

http://www.adamispharmaceuticals.com/

Latest From Adamis Pharmaceuticals Corporation

New Era For Schizophrenia Therapy Beckons As Karuna Soars On Promising Phase III Data

The PureTech Health-founded entity believes it has made a significant step forward in the treatment of schizophrenia with its muscarinic-receptor acting agent KarXT, which could offer a completely new way to address all three symptom domains of the disease.

Clinical Trials Companies

From Decoupling To Delisting: Might Biden-Xi Talks Ease Biotech Overhang?

While a two-hour-plus online discussion between the leaders of the world's two largest economies had some encouraging signs for the biopharma sector, more remains to be done and multiple other factors are playing into a mix of decoupling pressures.

China United States

Finance Watch: Big Money For Private Biopharma As Start-Up Areteia Raises $350m

Private Company Edition: As venture capital funding continues at a robust pace relative to public company financings, Knopp Biosciences and Population Health Partners launched Areteia with enough cash to fund Phase III asthma trials and Qiming revealed new VC funds totaling $2.5bn and $700m.

Financing Innovation

US Delisting Risk Hits I-Mab Hard, Bilateral Agreement Needed?

It started with the risk of delisting from US stock markets over auditing requirements, but there are other underlying risks for Chinese bioventures that ultimately only some form of bilateral governmental agreement may need to address, but this may be increasingly hard to reach.

Financing Compliance
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Biosyn Inc.
    • Cellegy Holdings Inc
    • US Compounding, Inc.
UsernamePublicRestriction

Register